Agios to Participate in March Investor Conferences

Rhea-AI Summary

Agios Pharmaceuticals (NASDAQ: AGIO) announced its participation in two investor conferences scheduled for March 2023. The Cowen 43rd Annual Health Care Conference is set for March 6 at 1:30 p.m. ET, followed by the Oppenheimer 33rd Annual Healthcare Conference on March 13 at 12:00 p.m. ET. Live webcasts of these presentations will be available on Agios’s website under the 'Events & Presentations' section, with replays archived for two weeks post-event. Agios is recognized for its innovative therapies aimed at rare diseases and is advancing a strong clinical pipeline.

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the following March investor conferences:

• Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 1:30 p.m. ET; and
• Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023 at 12:00 p.m. ET.

Live webcasts of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.

About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has a PAH stabilizer in preclinical development as a potential treatment for phenylketonuria (PKU) and deep scientific expertise in classical hematology. For more information, please visit the company’s website at www.agios.com.

Investor & Media Contact
Jessica Rennekamp
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com

FAQ

When is Agios Pharmaceuticals presenting at investor conferences in March 2023?

Agios Pharmaceuticals will present at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 1:30 p.m. ET and the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 12:00 p.m. ET.

Where can I watch the webcasts of Agios Pharmaceuticals' presentations?

The live webcasts of Agios Pharmaceuticals' presentations can be accessed under the 'Events & Presentations' section on their website, www.agios.com.

What is Agios Pharmaceuticals known for in the biopharmaceutical industry?

Agios Pharmaceuticals is known for pioneering therapies for rare diseases and has developed the first disease-modifying therapy for pyruvate kinase deficiency.

What types of diseases does Agios Pharmaceuticals target with its therapies?

Agios targets rare diseases, including alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, and MDS-associated anemia.

What is the ticker symbol for Agios Pharmaceuticals?

The ticker symbol for Agios Pharmaceuticals is AGIO, listed on NASDAQ.